Halozyme Therapeutics
HALO
110.79
+1.07
+0.98%
Halozyme Therapeutics
US · HALO
#1276 by market cap
Listed 1970
110.79
+1.07
+0.98%
Live - 5344 symbols - heartbeat 258s ago
· 2026-10-08 08:36
Pre-market
110.02
-0.70%
After-hours
110.79
0.00%
Overnight
110.00
-0.71%
- Market cap
- 12.57B
- P/E (TTM)i
- 32.49
- P/Bi
- 87.58
- EPSi
- 2.56
- Div yieldi
- 0.00%
- 52W posi
- 89%
Reader sentiment
Are you bullish or bearish on HALO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.99, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +37.55% YoY
Margins
- Gross margin
- 83.62%
- Operating margin
- 57.47%
- Net margin
- 22.69%
Key ratios & quality
- PEG ratioi
- 2.01
- Altman Z-Scorei
- 4.99
PEG uses trailing P/E against the 3-year net income growth rate (16.17%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 151.86M | 195.99M | 267.59M | 443.31M | 660.12M | 829.25M | 1.02B | 1.40B |
| Gross profit | 141.73M | 150.45M | 224.23M | 361.90M | 520.81M | 636.89M | 855.91M | 1.17B |
| Selling & admin expenses | 60.80M | 77.25M | 45.74M | 50.32M | 143.53M | 149.18M | 154.34M | 207.09M |
| Research & development | 150.25M | 140.80M | 34.24M | 35.67M | 66.61M | 76.36M | 79.05M | 81.49M |
| Operating profit | -69.33M | -67.61M | 144.26M | 275.90M | 267.53M | 337.57M | 551.48M | 802.59M |
| Pretax profit | -79.79M | -72.25M | 129.30M | 248.52M | 248.92M | 348.33M | 557.13M | 466.88M |
| Tax | 537.00K | -11.00K | 217.00K | -154.19M | 46.79M | 66.74M | 113.04M | 149.99M |
| Net profit | -80.33M | -72.24M | 129.09M | 402.71M | 202.13M | 281.59M | 444.09M | 316.89M |
| Basic EPS | -1 | -1 | 1 | 3 | 1 | 2 | 4 | 3 |
| Diluted EPS | -0.56 | -0.50 | 0.91 | 2.74 | 1.44 | 2.10 | 3.43 | 2.56 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 264.86M | 325.72M | 354.26M | 451.77M | 376.71M | 481.00M |
| Gross profit | 216.46M | 279.36M | 299.02M | 373.00M | 297.47M | 401.83M |
| Selling & admin expenses | 42.36M | 41.61M | 46.09M | 77.03M | 57.88M | 57.00M |
| Research & development | 14.80M | 17.54M | 17.25M | 31.90M | 25.56M | 27.66M |
| Operating profit | 141.54M | 202.44M | 217.92M | 240.70M | 184.52M | 287.65M |
| Pretax profit | 143.83M | 204.94M | 218.96M | -100.85M | 180.33M | 284.90M |
| Tax | 25.73M | 39.78M | 43.73M | 40.74M | 30.28M | 54.99M |
| Net profit | 118.10M | 165.16M | 175.23M | -141.59M | 150.05M | 229.91M |
| Basic EPS | 1 | 1 | 1 | -1 | 1 | 2 |
| Diluted EPS | 0.93 | 1.33 | 1.43 | -1.20 | 1.22 | 1.90 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 427.85M | 543.44M | 554.76M | 926.29M | 739.01M | 746.42M | 1.09B | 825.21M |
| Cash & ST investments | 354.53M | 421.26M | 368.01M | 740.92M | 362.79M | 336.00M | 596.07M | 142.82M |
| Inventory | 22.63M | 29.36M | 60.75M | 53.91M | 100.12M | 127.60M | 141.86M | 176.48M |
| Total assets | 440.25M | 565.87M | 579.92M | 1.10B | 1.84B | 1.73B | 2.06B | 2.53B |
| Total current liabilities | 149.36M | 85.64M | 421.39M | 117.15M | 130.79M | 112.49M | 139.10M | 177.09M |
| Short-term debt | 91.51M | 19.54M | 397.23M | 89.42M | 13.33M | -- | -- | -- |
| Long-term debt | 34.87M | 383.05M | -- | 787.26M | 1.49B | 1.50B | 1.51B | 2.14B |
| Total liabilities | 191,361,000.00 | 474,109,000.00 | 428,877,000.00 | 907,476,000.00 | 1,671,713,000.00 | 1,649,462,000.00 | 1,699,656,000.00 | 2,476,509,000.00 |
| Total equity | 248.89M | 91.77M | 151.05M | 196.95M | 169.80M | 83.81M | 363.82M | 48.81M |
| Retained earnings | -531.44M | -603.68M | -474.59M | -58.91M | 143.22M | 90.55M | 359.87M | 54.79M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.26B | 1.12B | 1.33B | 825.21M | 1.00B | 933.02M |
| Cash & ST investments | 747.92M | 548.18M | 701.96M | 142.82M | 318.62M | 231.00M |
| Inventory | 164.87M | 181.51M | 185.80M | 176.48M | 155.47M | 137.14M |
| Total assets | 2.20B | 2.05B | 2.22B | 2.53B | 2.67B | 2.58B |
| Total current liabilities | 150.38M | 134.28M | 837.23M | 177.09M | 363.21M | 344.44M |
| Short-term debt | -- | -- | 710.69M | -- | 208.74M | 208.97M |
| Long-term debt | 1.51B | 1.51B | 800.07M | 2.14B | 1.94B | 1.94B |
| Total liabilities | 1,714,262,000.00 | 1,721,151,000.00 | 1,717,317,000.00 | 2,476,509,000.00 | 2,453,083,000.00 | 2,433,865,000.00 |
| Total equity | 482.27M | 332.75M | 503.92M | 48.81M | 219.64M | 143.54M |
| Retained earnings | 477.96M | 361.03M | 502.15M | 54.79M | 204.84M | 151.26M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -49.50M | -85.42M | 55.45M | 299.44M | 240.11M | 388.57M | 479.06M | 651.56M |
| Depreciation & amortization | 2.39M | 4.07M | 3.28M | 3.00M | 49.64M | 84.86M | 81.31M | 88.05M |
| Free cash flow | -54.16M | -89.46M | 52.95M | 297.98M | 235.30M | 373.28M | 468.37M | 356.82M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -200.00M | -150.12M | -350.06M | -200.00M | -402.38M | -250.00M | -342.37M |
| Ending cash balance | 58.44M | 120.68M | 148.20M | 119.22M | 234.70M | 118.37M | 115.85M | 136.42M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 154.22M | 99.71M | 178.60M | 219.03M | 180.08M | 240.89M |
| Depreciation & amortization | 20.45M | 20.50M | 20.42M | 26.68M | 33.73M | 33.97M |
| Free cash flow | 153.27M | 98.15M | 175.57M | -70.17M | 176.34M | 236.72M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -38.88M | 0 | -- | -- |
| Ending cash balance | 176.33M | 61.86M | 419.67M | 136.42M | 312.01M | 163.99M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -35.14 | -42.41 | 106.33 | 231.44 | 110.23 | 222.07 | 198.42 | 153.59 |
| ROA %i | -16.73 | -14.36 | 22.53 | 47.82 | 13.72 | 15.75 | 23.39 | 13.81 |
| ROIC %i | -17.09 | -13.94 | 45.31 | 33.89 | 15.70 | 18.29 | 26.56 | 16.21 |
| 5-year avg ROE %i | -527.82 | -408.27 | -371.72 | 66.36 | 74.09 | 125.53 | 173.70 | 183.15 |
| EBIT margin %i | -40.66 | -30.93 | 55.94 | 57.76 | 40.28 | 44.27 | 56.65 | 34.73 |
| FCF / sales %i | -- | -- | 19.79 | 67.22 | 35.65 | 45.01 | 46.13 | 25.55 |
| Current ratioi | 2.86 | 6.35 | 1.32 | 7.91 | 5.65 | 6.64 | 7.80 | 4.66 |
| Quick ratioi | 2.57 | 5.61 | 1.11 | 7.10 | 4.54 | 5.07 | 6.50 | 3.30 |
| Debt / assetsi | 28.71 | 71.14 | 68.50 | 79.38 | 81.79 | 86.50 | 72.97 | 84.85 |
| LT debt / equityi | 14.01 | 417.42 | -- | 399.72 | 879.14 | 1,788.91 | 413.88 | 4,389.38 |
| Interest coveragei | -3.42 | -5.21 | 7.35 | 34.02 | 15.69 | 19.57 | 31.79 | 26.76 |
| Revenue CAGR (3Y) %i | 3.99 | 10.14 | -5.45 | 42.92 | 49.90 | 45.79 | 31.82 | 28.38 |
| Net income CAGR (3Y) %i | -- | -- | 27.03 | -- | -- | 29.69 | 3.31 | 16.17 |
| FCF CAGR (3Y) %i | -- | -- | -26.38 | -- | -- | 91.74 | 16.27 | 14.89 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 147.06 | 179.14 | 124.50 | 153.59 | 99.40 | 173.67 |
| ROA %i | 24.04 | 27.70 | 27.45 | 13.81 | 14.33 | 17.86 |
| ROIC %i | 27.25 | 31.47 | 26.04 | 16.21 | 15.87 | 19.72 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 57.46 | 60.25 | 61.45 | 34.73 | 34.64 | 36.28 |
| FCF / sales %i | 45.72 | 45.87 | 48.47 | 25.55 | 25.18 | 31.16 |
| Current ratioi | 8.39 | 8.36 | 1.59 | 4.66 | 2.76 | 2.71 |
| Quick ratioi | 7.00 | 6.44 | 1.25 | 3.30 | 2.14 | 1.99 |
| Debt / assetsi | 68.63 | 73.47 | 68.01 | 84.85 | 80.24 | 83.29 |
| LT debt / equityi | 312.57 | 453.53 | 158.77 | 4,389.38 | 881.41 | 1,349.90 |
| Interest coveragei | 34.40 | 39.49 | 43.01 | 26.76 | 27.34 | 29.73 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research, development and commercialization of our proprietary enzymes, devices, Hypercon technology100.00%
Quote time 2026-10-08 08:36:39 · For reference only, not investment advice and not tailored to your situation.